A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

Inclusion Criteria:

1. Participant must be ≥12 years of age, at the time of signing the electronic informedconsent form (eICF). For participants from 12 years of age to age of majority, theirparents/legal guardian must provide signed consent, as appropriate, and participantswill sign an assent form.

2. Diagnosis of asthma by a prescribing healthcare professional. Protocol-specifieddocumentation of asthma diagnosis is required to confirm diagnosis of asthma.

3. Participants actively using SABA alone or SABA on a background of either low-doseICS or LTRA.

4. Self-reported use of a SABA on ≥2 occasions, in response to symptoms (ie, not forexercise prophylaxis only), in the previous 2 weeks prior to enrollment.

5. An Asthma Impairment and Risk Questionnaire (AIRQ) score of ≥2 at Screening (Visit1/re-screen) and Randomisation (Randomization (Visit2) where applicable. Note,where screening Visit1/re-screen and randomization occur on the same day, AIRQ willonly be completed once.

6. Females of child-bearing potential must have a negative pregnancy test prior torandomization and agree to use an acceptable method of contraception throughout thestudy.

7. Male participants who are in heterosexual relationships must be surgically sterileor agree to use an effective method of contraception (condom) if the female partnerdoes not use contraception from the date the eICF is signed until 2 weeks aftertheir last dose.

Exclusion Criteria:

1. Any evidence of significant lung disease other than asthma, such as chronicobstructive pulmonary disease, emphysema, idiopathic pulmonary fibrosis, sarcoidosisetc or any other significant disease (like malignancies or severe chronic diseases)that by Investigator judgment would interfere with the participant being able tocomply with study procedures or complete the study.

2. Hospitalization due to asthma in the 3 months prior to enrollment or self-reportedadmission to the Intensive Care Unit with life-threatening asthma at any time in thepast

3. Self-reported use of inhaled Long-Acting Beta-Agonists (LABA), theophylline, inhaledanticholinergic agent, cromone or medium/high dose ICS daily, as regular maintenanceasthma therapy in the 3 months prior to enrollment

4. Self-reported use of systemic corticosteroids (SCS) for the treatment of asthma andany other condition in the 6 weeks prior to enrollment

5. Participants with a home supply of oral corticosteroids (OCS) to be used in the caseof an asthma exacerbation or any other condition that could require a course of OCS,who are not willing to commit to the treating physician to stop using thismedication for the duration of the study.

6. Receipt of any marketed (eg, omalizumab, mepolizumab, reslizumab, benralizumab,dupilumab, tezepelumab) or investigational biologic for the treatment of asthma atany time in the past

7. Receipt of bronchothermoplasty

8. Use of a SABA prophylactically primarily to prevent exercise induced bronchospasm (EIB) and not to treat symptoms

9. Currently receiving systemic treatment with potent cytochrome P3A4 inhibitors (eg,ketoconazole, itraconazole, and ritonavir)

10. Judgment by the Investigator that the participant should not participate in thestudy if the participant is unlikely to comply with study procedures, restrictions,and requirements.

11. Previous screening, enrollment or randomization in the present study.

12. For females only - currently pregnant (confirmed with positive pregnancy test) orbreastfeeding.

13. Participants without access to a smartphone or the internet.